|Bid||62.71 x 40000|
|Ask||63.23 x 1800|
|Day's range||61.85 - 63.13|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||17.62|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||2.92 (4.67%)|
|Ex-dividend date||14 Jun 2022|
|1y target est||69.21|
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
FOSTER CITY, Calif., June 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Shares of Gilead Sciences (NASDAQ: GILD) and Best Buy (NYSE: BBY) have fallen more than 19% this year. Are these dividend stocks potential steals right now, or should you be worried about a possible cut to their above-average payouts? Gilead's 19% year-to-date decline has actually been modest, compared to the S&P 500, which is down 23% over the same time frame.